Abemaciclib is a medication regulated by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of breast cancer [1][2]. It is specifically approved for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer [2][3].
What types of breast cancer is abemaciclib used for?
Abemaciclib is indicated for HR-positive, HER2-negative advanced or metastatic breast cancer [2][3]. It can be used as an initial treatment in combination with an aromatase inhibitor or fulvestrant, or as a treatment for patients who have received prior endocrine therapy [2][4].
How does abemaciclib work?
Abemaciclib is a type of targeted therapy known as a cyclin-dependent kinase (CDK) inhibitor [1][5]. It works by inhibiting CDK4 and CDK6, enzymes that play a role in cell growth and division [1][5]. In breast cancer cells, these enzymes can be overactive, promoting uncontrolled tumor growth. By blocking CDK4/6, abemaciclib can help slow or stop the growth of cancer cells [1][5].
What is the brand name for abemaciclib?
Abemaciclib is marketed under the brand name Verzenio [1][2].
What are the potential side effects of abemaciclib?
Common side effects associated with abemaciclib include diarrhea, neutropenia (low white blood cell count), nausea, fatigue, decreased appetite, and abdominal pain [3][6]. Serious side effects can include severe diarrhea, liver problems, blood clots, and lung inflammation [3][6]. Patients are advised to report any new or worsening symptoms to their healthcare provider [3][6].
How is abemaciclib administered?
Abemaciclib is taken orally, typically twice a day [2][3]. It is usually administered in combination with other medications, depending on the patient's treatment regimen [4].
What is the regulatory status of abemaciclib?
Abemaciclib received its initial FDA approval in 2017 [1]. Since then, its indications have been expanded based on further clinical trial data [4]. It is subject to ongoing FDA oversight regarding its safety and efficacy [1].
What other CDK4/6 inhibitors are available?
Other CDK4/6 inhibitors approved by the FDA for similar breast cancer indications include palbociclib (Ibrance) and ribociclib (Kisqlyx) [7][8][9]. These drugs also target CDK4 and CDK6 but have different administration schedules and side effect profiles [7][8][9].
What are the clinical trial results supporting abemaciclib's approval?
Abemaciclib's approvals are based on data from pivotal clinical trials, such as the monarch 3, monarch 2, and monarch 1 studies, which demonstrated significant improvements in progression-free survival and, in some cases, overall survival for patients treated with abemaciclib compared to placebo or other treatments [1][2][4].
Are there any specific patient populations for whom abemaciclib is not recommended?
Abemaciclib may not be suitable for individuals with a history of severe hypersensitivity reactions to the drug or its components [3]. Dosage adjustments may be necessary for patients with severe liver impairment [3].
Who manufactures abemaciclib?
Abemaciclib (Verzenio) is manufactured by Eli Lilly and Company [1][2].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/verzenio-abemaciclib
[2] https://www.verzenio.com/
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209785s039,211110s007lbl.pdf
[4] https://www.fda.gov/drugs/drug-approvals/verzenio-abemaciclib-expanded-treatment-options-patients-hr-positive-her2-negative-advanced-or-metastatic
[5] https://www.cancer.gov/about-cancer/treatment/drugs/abemaciclib
[6] https://www.webmd.com/drugs/2/234137/abemaciclib-oral
[7] https://www.fda.gov/drugs/drug-approvals/ibrance-palbociclib
[8] https://www.fda.gov/drugs/drug-approvals/kisqlyx-ribociclib
[9] https://www.cancernetwork.com/view/cdk4-6-inhibitors-in-breast-cancer-a-comparative-review